NASDAQ:ATNF - Nasdaq - US68236V3024 - Common Stock - Currency: USD
1.18
-0.02 (-1.67%)
The current stock price of ATNF is 1.18 USD. In the past month the price decreased by -14.49%. In the past year, price decreased by -66.57%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California and currently employs 4 full-time employees. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
180 LIFE SCIENCES CORP
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto CALIFORNIA 10019 US
CEO: James N. Woody
Employees: 4
Company Website: https://180lifesciences.com/
Phone: 16505070669
The current stock price of ATNF is 1.18 USD. The price decreased by -1.67% in the last trading session.
The exchange symbol of 180 LIFE SCIENCES CORP is ATNF and it is listed on the Nasdaq exchange.
ATNF stock is listed on the Nasdaq exchange.
180 LIFE SCIENCES CORP (ATNF) has a market capitalization of 3.75M USD. This makes ATNF a Nano Cap stock.
180 LIFE SCIENCES CORP (ATNF) currently has 4 employees.
180 LIFE SCIENCES CORP (ATNF) has a resistance level at 1.27. Check the full technical report for a detailed analysis of ATNF support and resistance levels.
The Revenue of 180 LIFE SCIENCES CORP (ATNF) is expected to grow by 481.87% in the next year. Check the estimates tab for more information on the ATNF EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ATNF does not pay a dividend.
180 LIFE SCIENCES CORP (ATNF) will report earnings on 2025-03-20, after the market close.
180 LIFE SCIENCES CORP (ATNF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.49).
The outstanding short interest for 180 LIFE SCIENCES CORP (ATNF) is 0.85% of its float. Check the ownership tab for more information on the ATNF short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ATNF. ATNF has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ATNF reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 98.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.82% | ||
ROE | -83.61% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ATNF. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 50% and a revenue growth 481.87% for ATNF